AbCellera Biologics Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AbCellera Biologics Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-09-30 was $899.00K, a 10.19% decline year-over-year.
- AbCellera Biologics Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-06-30 was $1.78M, a 4841.67% increase year-over-year.
- AbCellera Biologics Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-03-31 was $173.00K, a 39.52% increase year-over-year.
- AbCellera Biologics Inc. stock issued during period, value, stock options exercised for the quarter ending 2020-09-30 was $1.00M.
- AbCellera Biologics Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $942.00K, a 3668.00% increase from fiscal 2019.
- AbCellera Biologics Inc. stock issued during period, value, stock options exercised for fiscal 2019 was $25.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2021-09-30 | $899.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $1.78M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $173.00K 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $942.00K 10-K · filed 2023-02-21 | |
| 2020-09-30 | $1.00M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $36.00K 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $124.00K 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $25.00K 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |